Overview

TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated mCRC

Status:
Completed
Trial end date:
2015-06-18
Target enrollment:
Participant gender:
Summary
Primary Objective: To determine disease control rate (DCR) of TS-1® in patients with heavily pre-treated metastatic colorectal cancer Secondary Objectives: - To determine objective response rate (ORR) - To determine time to progression (TTP) - To determine overall survival (OS) - To assess incidence of adverse events (AEs), serious adverse events (SAEs) [Safety and Tolerability]
Phase:
Phase 2
Details
Lead Sponsor:
TTY Biopharm
Collaborator:
Chang Gung Memorial Hospital
Treatments:
Calcium, Dietary
Leucovorin
Levoleucovorin